A group of antibody compositions for detecting trace tissue samples to screen blood tumors and their applications

By using cocktail combination technology with 14 antibody compositions in the detection of microtissue samples, the problems of insufficient cell quantity and necrosis interference in the prior art are solved, and high sensitivity and high accuracy screening of microtissues are achieved, which is suitable for Detection of micro-samples such as lymph nodes.

CN118091137BActive Publication Date: 2024-11-05TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311716423.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-14
Publication Date
2024-11-05
Estimated Expiration
2043-12-14

AI Technical Summary

Technical Problem

The prior art requires at least 2 tubes of cell volume when detecting microtissue samples, and necrotic tissue and debris interfere with the analysis of the results, resulting in a decrease in detection sensitivity and accuracy.

Method used

Provide a set of antibody compositions for detecting microtissue samples, including 14 antibodies (anti-CD5, CD19, CD45, CD4, kappa, Lambda, CD56, 7-AAD, CD7, CD3, CD138, CD20, CD8, etc. ), the cocktail combination principle is used to screen in a single sample container, and the anti-7-AAD antibody is used to eliminate necrotic cells to improve detection accuracy.

Benefits of technology

Accurate screening in microcell samples is achieved, the sensitivity and accuracy of detection is improved, the sample usage is reduced, and it is suitable for screening of micro samples such as lymph nodes and punctures, simplifying the operation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118091137B_ABST
    Figure CN118091137B_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of antibody detection, and in particular to a group of antibody compositions for detecting trace tissue samples for screening blood tumors and their applications; the antibody composition comprises anti-CD5 antibody, anti-CD19 antibody, anti-CD45 antibody, anti-CD4 antibody, anti-kappa antibody, anti-CD56 antibody, anti-Lambda antibody, anti-7-AAD antibody, anti-CD7 antibody, anti-CD3 antibody, anti-CD138 antibody, anti-CD38 antibody, anti-CD20 antibody and anti-CD8 antibody; the antibody composition can be used for screening B, T, NK and plasma cell tumors in a one-tube method, and is applied to the initial screening of small amounts of tissue samples. The one-tube initial screening can save samples, and one tube of samples can be kept for additional testing. At the same time, the addition of anti-7-AAD antibody can eliminate the interference of necrotic cells in the tissue sample, thereby improving the sensitivity and specificity of the diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of antibody detection, and in particular to a group of antibody compositions and applications thereof for detecting trace tissue samples for screening blood tumors. Background Art

[0002] With the increasing popularity and advancement of diagnostic imaging tools such as computed tomography (CT) and magnetic resonance imaging (MRI), the detection rate of mediastinal and abdominal lymphomas is also on the rise. Clear histopathological results are crucial for accurate diagnosis and staging, and are also crucial for drug-based treatment. Compared with superficial lymph nodes in the head, enlarged deep lymph nodes in the neck and axillary areas are usually unable to be examined by puncture biopsy of the target lesion tissue. Therefore, open exploration or thoracoscopic combined with laparoscopic methods are generally used. Although these methods can provide a large number of biopsy tissue samples for comprehensive pathological examinations, they are highly invasive and increase economic costs.

[0003] Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) or endoscopic ultrasound-guided fine needle biopsy (FNB) is safe, sensitive, and economical, and has become a widely used and effective tool for diagnosing deep thoracic and abdominal lymphomas. It is rapidly becoming the preferred diagnostic method for collecting masses in the mediastinum, upper gastrointestinal tract, pancreas, and liver, and may replace the above invasive methods. However, the accuracy of EUS-FNA is between 50.0% and 99.4%, and the accuracy also depends on the location of the lymph nodes. In the medical field, flow cytometry (FCM) combined with monoclonal immunofluorescent antibodies has become a technology that can quantitatively detect cell surface, intracellular antigens, and membrane receptors. Compared with immunohistochemistry (IHC), FCM has the advantages of fast detection speed, high sensitivity, and low sample analysis cost. Therefore, FCM can provide unique diagnostic insights when conventional histological evaluation is uncertain. At present, studies have shown that FCM combined with EUS-FNA has higher sensitivity and accuracy. Due to the fast detection speed of FCM, it can be used for rapid diagnosis of critically ill patients. For tissue samples with a small number of cells or multiple tumor cells coexisting, FCM can analyze tumor cells independently. It has the characteristics of high sensitivity and high specificity, and can significantly improve the sensitivity and specificity of puncture biopsy diagnosis. At the same time, this technology is especially suitable for patients who cannot obtain surgical resection tissue samples and can only obtain a small amount of biopsy samples, or patients who cannot be diagnosed after repeated sampling, especially patients with blood tumors such as lymphoma, plasma cell tumors, and myeloid tumors. Lesions often occur in extramedullary tissues. Therefore, FCM has become a basic auxiliary tool for diagnosing lymphoproliferative diseases, and is also one of the important detection methods for the diagnosis, classification, efficacy monitoring, and prognosis evaluation of blood tumors.

[0004] At present, the comprehensive and accurate diagnosis of nine major types of leukemia / lymphoma using FCM requires nearly 90 antibodies (about 23 myeloid-related markers, about 30 B-lineage and plasma cell-related markers, about 22 T-lineage-related markers, and about 14 NK-related markers). Considering the main disease range involved in FCM detection of tissue samples and the particularity of small sample volume of tissue samples, in order to make the best possible use of samples and achieve accurate diagnosis of different diseases, the current clinical test mostly adopts a two-step method, that is, in the first step, a relatively small number of antibodies are used to perform preliminary screening of B-NHL, T-NHL, NK-NHL, and plasma cell diseases on the samples to be tested, and the corresponding antibodies are selected for the second step detection according to the results of the first step classification. The second step is mainly for disease subtyping, trace residual disease monitoring, and prognosis-related and treatment targets, as well as screening of genetic abnormality-related markers. Through the two-step detection, each type of leukemia and lymphoma can be accurately and comprehensively diagnosed using relatively few antibodies. However, puncture or endoscopic biopsy samples often face the problem of insufficient cells. Therefore, when the tissue sample is sent for lymphoma screening, when the cell quantity is extremely small, it is necessary to prioritize screening for tumors derived from B, T, NK, and plasma cells. However, conventional flow cytometry screening uses a separate tube for T, NK, and B cells, so at least 2 tubes of cells are required for testing, which is complicated to operate. At the same time, compared with conventional bone marrow and peripheral blood, tissue samples are more likely to have a large amount of necrotic tissue and debris, which will interfere with the analysis of the results. Summary of the invention

[0005] The present application provides a group of antibody compositions and applications thereof for detecting trace tissue samples for screening blood tumors, in order to solve the technical problems in the prior art that conventional flow cytometry screening requires at least 2 tubes of cells for detection and that necrotic tissue and debris interfere with the result analysis.

[0006] In the first aspect, the present application provides a group of antibody compositions for detecting trace tissue samples for screening blood tumors, wherein the antibody composition includes anti-CD5 antibodies, anti-CD19 antibodies, anti-CD45 antibodies, anti-CD4 antibodies, anti-kappa antibodies, anti-CD56 antibodies, anti-Lambda antibodies, anti-7-AAD antibodies, anti-CD7 antibodies, anti-CD3 antibodies, anti-CD138 antibodies, anti-CD38 antibodies, anti-CD20 antibodies and anti-CD8 antibodies.

[0007] Optionally, the volume ratio of the anti-CD5 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0008] The volume ratio of the anti-CD19 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0009] The volume ratio of the anti-CD45 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0010] The volume ratio of the anti-kappa antibody to the antibody composition is 0.02 to 0.03; and / or,

[0011] The volume ratio of the anti-CD4 antibody to the antibody composition is 0.12 to 0.13; and / or,

[0012] The volume ratio of the anti-Lambda antibody to the antibody composition is 0.02 to 0.03; and / or,

[0013] The volume ratio of the anti-CD56 antibody to the antibody composition is 0.12 to 0.13; and / or,

[0014] The volume ratio of the anti-7-AAD antibody to the antibody composition is 0.12 to 0.13; and / or,

[0015] The volume ratio of the anti-CD7 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0016] The volume ratio of the anti-CD3 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0017] The volume ratio of the anti-CD138 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0018] The volume ratio of the anti-CD38 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0019] The volume ratio of the anti-CD8 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0020] The volume ratio of the anti-CD20 antibody to the antibody composition is 0.05 to 0.06.

[0021] Optionally, the antibody composition is a fluorescently labeled antibody composition, and the fluorescent marker used in the fluorescent labeling comprises at least one of the following:

[0022] At least one of BV605, BV421, V500-C, FITC, PE, PerCP-cy5.5, PE-Cy7, APC, APC-R700 and APC-Cy7.

[0023] Optionally, the fluorescein of the anti-CD5 antibody is BV605; and / or,

[0024] The fluorescein of the anti-CD19 antibody is BV421; and / or,

[0025] The fluorescein of the anti-CD45 antibody is V500-C; and / or,

[0026] The fluorescein of the anti-kappa antibody is FITC; and / or,

[0027] The fluorescein of the anti-CD4 antibody is FITC; and / or,

[0028] The fluorescein of the anti-Lambda antibody is PE; and / or,

[0029] The fluorescein of the anti-CD56 antibody is PE; and / or,

[0030] The fluorescein of the anti-7-AAD antibody is PerCP-cy5.5; and / or,

[0031] The fluorescein of the anti-CD7 antibody is PE-Cy7; and / or,

[0032] The fluorescein of the anti-CD3 antibody is APC; and / or,

[0033] The fluorescein of the anti-CD138 antibody is APC; and / or,

[0034] The fluorescein of the anti-CD38 antibody is APC-R700; and / or,

[0035] The fluorescein of the anti-CD8 antibody is APC-Cy7; and / or,

[0036] The fluorescein of the anti-CD20 antibody is APC-Cy7.

[0037] Optionally, the anti-Kappa antibody is a polyclonal antibody.

[0038] Optionally, the anti-Lambda antibody is a polyclonal antibody.

[0039] In a second aspect, the present application provides a group of antibody compositions for detecting trace tissue samples to screen blood tumors, and the antibody composition described in the first aspect is used in screening reagents for screening trace cell samples.

[0040] Optionally, the screening steps are:

[0041] Adding the antibody composition to a trace amount of cell sample in a single sample container, and then performing a first incubation to obtain an incubated sample;

[0042] The incubation sample and hemolysin are mixed, and a second incubation is performed, followed by centrifugation and PBS washing to obtain a resuspended cell solution;

[0043] The resuspended cell solution is subjected to flow cytometry detection to complete the screening.

[0044] Optionally, the first incubation time is 10 min to 20 min.

[0045] Optionally, the second incubation time is ≥5 min.

[0046] The above technical solution provided by the embodiment of the present application has the following advantages compared with the prior art:

[0047] The embodiment of the present application provides a group of antibody compositions for detecting trace tissue samples for screening blood tumors. By using 14 antibodies in combination, compared with the traditional two-tube antibody composition, different antibody combinations are matched using the principle of cocktail combination. Based on the number of trace cell samples in a single sample container, only 14 antibodies are added to complete the accurate screening of trace cell samples in one sample container, avoiding the use of at least two tubes in the prior art, which causes the number of cells in multiple tubes to be too small and reduces the sensitivity. At the same time, the introduced anti-7-AAD antibody can effectively exclude necrotic cells in tissue samples, avoid necrotic tissue and debris interfering with the analysis results, help to improve the accuracy of screening, and greatly save samples. The one-tube method is simple and economical to use for screening T cells, B cells, NK cells and plasma cells for abnormal immunophenotypes. It can be widely used in the screening of trace samples such as lymph nodes, punctures, and skin tissues. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0049] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0050] Figure 1 A schematic diagram of a logical gating method recommended for a group of antibody compositions for detecting trace tissue samples for screening blood tumors in screening normal lymph node tissues provided in an embodiment of the present application;

[0051] Figure 2 A schematic diagram of the screening process provided in the embodiment of the present application;

[0052] Figure 3 A schematic diagram of an example result of the initial screening of extramedullary multiple myeloma (MM) provided in an embodiment of the present application;

[0053] Figure 4A schematic diagram of an example result of the initial screening of non-Hodgkin's B-cell lymphoma (B-NHL, DLBCL) provided in an embodiment of the present application;

[0054] Figure 5 A schematic diagram of an example result of the initial screening of B-lymphoblastic lymphoma / leukemia (B-LBL / ALL) provided in an embodiment of the present application;

[0055] Figure 6 A schematic diagram of an example result of the initial screening of non-Hodgkin's T-cell lymphoma (T-NHL, AITL) provided in an embodiment of the present application;

[0056] Figure 7 A schematic diagram of an example result of a preliminary screening of T-lymphoblastic lymphoma / leukemia (T-LBL / ALL) provided in an embodiment of the present application;

[0057] Figure 8 A schematic diagram of an example result of the initial screening of NK cell lymphoma provided in an embodiment of the present application;

[0058] Fig. 9 This is a schematic diagram of an example result of the initial screening of neuroblastoma provided in the embodiments of the present application. DETAILED DESCRIPTION

[0059] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0060] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0061] The creative thinking of this application is:

[0062] Currently, there is an 8-color EuroFlow antibody combination that uses a two-step method to immunotype acute and chronic leukemias and lymphomas. The solution includes LST (lymphoma screening tube) with a total of 12 antibodies; PCD (plasma cell clonal disease) detection tube, a total of 16 antibodies. Through the screening tube, B-NHL, T-NHL, NK-NHL, and PCN can be initially screened. The Chinese Journal of Pathology (vol46:217-222) published the "Expert Consensus on the Application of Flow Cytometry in the Diagnosis of Non-Hodgkin's Lymphoma", which states that a 2-tube antibody combination can be used for the screening of B-NHL, T, NK and plasma cell tumors. The antibody combination of the existing technology cannot achieve the purpose of comprehensive and accurate screening of blood tumors in trace tissue samples with a single tube.

[0063] Moreover, flow cytometry detection of tissue samples has not yet become a routine project. Most testing centers mainly use 2 tubes of antibody combination for primary screening. For samples with very few cells, if they are divided into 2 tubes for primary screening, the number of cells in each tube will be significantly reduced, which reduces the sensitivity of the test; if the cells in the 2 tubes are used up in the initial screening, the next step cannot be performed; in addition, there are often a large amount of necrosis and connective tissue in tissue samples that interfere with the analysis of the results, all of which affect the accuracy of the diagnosis; therefore, it is currently necessary to design a comprehensive, accurate, economical and efficient antibody combination for the initial screening of blood tumors for trace tissue samples to solve the actual clinical difficulties and benefit patients.

[0064] like Figure 1 As shown, the embodiments of the present application provide a group of antibody compositions for detecting trace tissue samples for screening blood tumors, and the antibody composition includes anti-CD5 antibody, anti-CD19 antibody, anti-CD45 antibody, anti-CD4 antibody, anti-kappa antibody, anti-CD56 antibody, anti-Lambda antibody, anti-7-AAD antibody, anti-CD7 antibody, anti-CD3 antibody, anti-CD138 antibody, anti-CD38 antibody, anti-CD20 antibody and anti-CD8 antibody.

[0065] It should be noted that the antibody composition can form a total of 14 antibodies including CD5 antibody, anti-CD19 antibody, anti-CD45 antibody, anti-CD4 antibody, anti-kappa antibody, anti-CD56 antibody, anti-Lambda antibody, anti-7-AAD antibody, anti-CD7 antibody, anti-CD3 antibody, anti-CD138 antibody, anti-CD38 antibody, anti-CD20 antibody and anti-CD8 antibody. These 14 antibodies can specifically bind to B, T, NK and plasma cells, respectively, and can complete the accurate screening of trace cell samples in a sample container. At the same time, the anti-7-AAD antibody can also effectively exclude necrotic cells in tissue samples, avoid necrotic tissue and debris interfering with the analysis results, and help improve the accuracy of screening.

[0066] In some optional embodiments, the volume ratio of the anti-CD5 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0067] The volume ratio of the anti-CD19 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0068] The volume ratio of the anti-CD45 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0069] The volume ratio of the anti-kappa antibody to the antibody composition is 0.02 to 0.03; and / or,

[0070] The volume ratio of the anti-CD4 antibody to the antibody composition is 0.12 to 0.13; and / or,

[0071] The volume ratio of the anti-Lambda antibody to the antibody composition is 0.02 to 0.03; and / or,

[0072] The volume ratio of the anti-CD56 antibody to the antibody composition is 0.12 to 0.13; and / or,

[0073] The volume ratio of the anti-7-AAD antibody to the antibody composition is 0.12 to 0.13; and / or,

[0074] The volume ratio of the anti-CD7 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0075] The volume ratio of the anti-CD3 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0076] The volume ratio of the anti-CD138 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0077] The volume ratio of the anti-CD38 antibody to the antibody composition is 0.07 to 0.08; and / or,

[0078] The volume ratio of the anti-CD8 antibody to the antibody composition is 0.05 to 0.06; and / or,

[0079] The volume ratio of the anti-CD20 antibody to the antibody composition is 0.05 to 0.06.

[0080] In the embodiment of the present application, the specific volume ratios of the 14 antibodies are defined, so that the specific addition amounts of the 14 antibodies can be clarified, thereby enabling accurate screening of trace cell samples in one sample container.

[0081] In some optional embodiments, the antibody composition is a fluorescently labeled antibody composition, and the fluorescent group used for the fluorescent labeling includes at least one of the following:

[0082] At least one of BV605, BV421, V500-C, FITC, PE, PerCP-cy5.5, PE-Cy7, APC, APC-R700 and APC-Cy7.

[0083] In some optional embodiments, the fluorescein of the anti-CD5 antibody is BV605; and / or,

[0084] The fluorescein of the anti-CD19 antibody is BV421; and / or,

[0085] The fluorescein of the anti-CD45 antibody is V500-C; and / or,

[0086] The fluorescein of the anti-kappa antibody is FITC; and / or,

[0087] The fluorescein of the anti-CD4 antibody is FITC; and / or,

[0088] The fluorescein of the anti-Lambda antibody is PE; and / or,

[0089] The fluorescein of the anti-CD56 antibody is PE; and / or,

[0090] The fluorescein of the anti-7-AAD antibody is PerCP-cy5.5; and / or,

[0091] The fluorescein of the anti-CD7 antibody is PE-Cy7; and / or,

[0092] The fluorescein of the anti-CD3 antibody is APC; and / or,

[0093] The fluorescein of the anti-CD138 antibody is APC; and / or,

[0094] The fluorescein of the anti-CD38 antibody is APC-R700; and / or,

[0095] The fluorescein of the anti-CD8 antibody is APC-Cy7; and / or,

[0096] The fluorescein of the anti-CD20 antibody is APC-Cy7.

[0097] In the embodiments of the present application, the specific fluorescent groups used for fluorescent labeling are limited, and the 14 antibodies can be fully labeled with these 10 fluorescent groups, so that accurate screening of trace cell samples can be completed in one sample container through 10 color channels.

[0098] In some optional embodiments, the anti-Kappa antibody is a polyclonal antibody.

[0099] In some optional embodiments, the anti-Lambda antibody is a polyclonal antibody.

[0100] Based on a general inventive concept, the embodiments of the present application provide a group of antibody compositions for detecting trace tissue samples for screening blood tumors, and the antibody compositions are used in screening reagents for screening trace cell samples.

[0101] This application is realized based on the above-mentioned antibody composition. The specific composition of the antibody composition can refer to the above-mentioned embodiment. Since this application adopts part or all of the technical solutions of the above-mentioned embodiment, it has at least all the beneficial effects brought by the technical solutions of the above-mentioned embodiment, which will not be described one by one here.

[0102] It should be noted that the trace cell samples include B, T, NK and plasma cell tumor samples.

[0103] like Figure 2 As shown, in some optional embodiments, the screening steps are:

[0104] S1. adding the antibody composition to a trace cell sample in a single sample container, and then performing a first incubation to obtain an incubated sample;

[0105] S2. mixing the incubation sample and the hemolysin, and performing a second incubation, followed by centrifugation and PBS washing to obtain a resuspended cell solution;

[0106] S3. Perform flow cytometry on the resuspended cell solution to complete the screening.

[0107] In the embodiments of the present application, the specific steps of screening are defined. Based on the antibody composition designed in the present application, the antibody composition can be mixed with a trace cell sample to react fully through a first incubation, and finally hemolysin is added for a subsequent second incubation, thereby completing accurate screening of a trace cell sample in a sample container.

[0108] In some optional embodiments, the first incubation time is 10 min to 20 min.

[0109] In some optional embodiments, the second incubation time is ≥5 min.

[0110] In the embodiments of the present application, the specific time of the first incubation is limited so that the antibody composition and the trace cell sample can be mixed and reacted sufficiently, thereby improving the accuracy of subsequent screening.

[0111] By limiting the specific time of the second incubation, the cells in the incubated sample after the antibody composition is mixed with the trace cell sample can be completely dissolved, thereby facilitating the subsequent acquisition of a specific antibody composition and a conjugate of the antigen in the trace cell sample, thereby improving the accuracy of the detection.

[0112] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are intended only to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are usually measured according to national standards. If there is no corresponding national standard, then the conditions recommended by the manufacturer are followed.

[0113] Example 1

[0114] 1. Experimental materials:

[0115] (1) Used for the initial screening of blood tumors in tissue samples, especially those with low cell count.

[0116] (2) Tissue samples submitted for examination by patients with fever, systemic lymphadenopathy, hepatosplenomegaly, local tissue space-occupying lesions, and clinical suspicion of lymphoma.

[0117] 2. Specimen type:

[0118] Lymph nodes, puncture materials, skin tissue, various endoscopic biopsy samples, etc.

[0119] 3. Instruments and reagents:

[0120] (1) Instrument: BD Canto II

[0121] (2) The antibody composition includes the following antibodies: anti-CD5 antibody, anti-CD19 antibody, anti-CD45 antibody, anti-kappa antibody, anti-CD4 antibody, anti-Lambda antibody, anti-CD56 antibody, anti-7-AAD antibody, anti-CD7 antibody, anti-CD3 antibody, anti-CD138 antibody, anti-CD8 antibody, and anti-CD20 antibody. Each antibody in the antibody composition is a fluorescein-labeled antibody. The specific antibodies and fluorescent labeling groups are shown in Table 1.

[0122] Table 1 Distribution of antibody compositions, monoclonal antibodies and fluorescent labeling groups used

[0123]

[0124]

[0125] 4. Experimental methods:

[0126] (1) Preparation and evaluation of single-cell suspensions: For samples from the thymus, spleen, lymph nodes, etc., single-cell suspensions are usually prepared manually. Laboratories with the necessary conditions can also use fully automatic tissue processors to prepare single-cell suspensions.

[0127] Manual preparation process: Place the tissue in a culture dish, rinse with saline, cut into pieces, and grind gently with a tissue grinder to avoid over-grinding and causing breakage. Filter with a 200-mesh sieve to remove the residue, centrifuge at 300g, wash, resuspend the cells with saline, count the cells, and adjust the cell concentration to 10 6 / mL~10 7 Pieces / mL;

[0128] For samples from solid organs such as the gastrointestinal tract, lungs, liver, skin, etc., since the tissues contain more connective tissue, they need to be chopped up before grinding and digestive enzymes added to digest on an oscillator at 37°C (different enzymes and tissues have slightly different digestion times, ranging from 15 minutes to 6 hours, please refer to the product manual for details). The digested tissues are then directly ground with a grinding rod. The subsequent steps and precautions are the same as the preparation of single-cell suspensions of immune organ tissues, and the cells are counted for later use.

[0129] (2) Add the sample to be tested into the flow cytometry tube to make it into a single cell suspension with a cell volume of 1×10 6 Pieces / tube-1×10 7 For very small amount of cells, such as punctured tissue, add half of the cells. The sample volume per tube usually does not exceed 150μL;

[0130] (3) Fill the sample obtained in step (2) with NH4CI and blow evenly with a pipette to lyse red blood cells for 10 minutes; wash the sample three times, centrifuge at 1300 rpm for 5 minutes, and remove the supernatant; mix with the antibody composition of the present invention, and incubate at room temperature in the dark for 10 to 20 minutes;

[0131] (4) Add 1× hemolysin to the flow tube after incubation in step (3) and incubate at room temperature in the dark for 5 min;

[0132] (5) Centrifuge the flow tube after incubation in step (4) to remove the supernatant (centrifugal force is 300g~450g for 5 minutes);

[0133] (6) Add PBS buffer to the flow tube in step (5), mix well, centrifuge to remove the supernatant, and resuspend the cells with PBS buffer (add about 500 μL);

[0134] (7) Perform flow cytometry on the resuspended cells in step (6) and analyze the results. The instrument used is a Canto II 3 laser 10-color flow cytometer from BD, USA.

[0135] 5. Data Analysis:

[0136] (1) The specimens were processed according to the above experimental method and tested on a 3-laser 10-color FACSCanto II flow cytometer from Becton Dickinson, USA. The gates were set as follows during the flow cytometer test:

[0137] ① Use the Time / CD45 dot plot to circle the liquid stability gate when the flow is stable, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0138] ②In the nucleated cell gate, observe the combination of CD45 / CD56 and CD45 / CD19 to see if there is CD45 - CD56 + Abnormal cells or CD45 - CD19 + Abnormal B cells or plasma cells;

[0139] ③ Plasma cells: Use CD138 / CD38 to circle plasma cells and non-plasma cells, and in the non-plasma cell gate, use CD45 / SSC to group lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations; analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38, and CD56;

[0140] ④B cells: circle B lymphocytes in the non-plasma cell gate using CD20 / CD19, and observe the expression of CD5, membrane light chain Kappa and Lambda of B cells;

[0141] ⑤T cells: In the lymphocyte gate, circle CD3 by CD3 / CD19 combination + T cells, CD19 + B cells and CD3 - CD19 - Cell population; in CD3 + The expression of T cell CD4 and CD8 was observed in the T cell gate, and the CD4 / CD8 ratio was calculated. Meanwhile, the expression of T cell CD4, CD8, CD7, CD5 and CD3 was observed in the nucleated cell gate;

[0142] ⑥T / NK cells: in CD3 - CD19 - Within the cell gate, the expression of CD5 on NK cells or abnormal T cells was analyzed using the CD56 / CD7 combination;

[0143] ⑦Other cells: in CD3 - CD19 - CD7 - Observe the expression of CD4, CD38, and CD5 within the gate to determine whether it is a monocyte or an abnormal T cell;

[0144] ⑧ Immature cells: First, observe the proportion of immature cell gates. When the proportion increases, pay special attention to the expression of CD7, CD5, CD19, CD10, CD56 and CD38. The specific gate logic is as follows: Figure 1 shown.

[0145] (2) Analysis of possible abnormal results of the screening tube:

[0146] 1) Plasma cells: In the gate of all nucleated cells, if CD38 bri+ CD138 + / - Cell populations, observing their positions in the CD45 / SSC plot and the expression of CD19, CD20, CD56, and light chains, may show the following:

[0147] ① Plasma cell phenotype is CD38 + CD138 + CD56 - / + CD19 - CD20 - / + CD45 - / dim+ , the cell SSC is large, which is suspected to be an abnormal plasma cell. Other plasma cell markers can be added to determine the plasma cell monoclonality and abnormal immune phenotype;

[0148] ② If monoclonal plasma cells are accompanied by monoclonal B cells, and the light chain expression of the two is consistent, mature B-cell lymphoma with plasma cell differentiation is often considered. This type of plasma cell is mostly CD45 + CD38bri + CD19 + CD20 + / - CD56 - ; If the expression of plasma cell and B cell light chain clonality is inconsistent, it may indicate a complex tumor;

[0149] ③ Plasma cell phenotype is CD45 + CD38 bri+ CD138 + CD19 + CD20 - CD56 -, the position of plasma cells in the CD45 / SSC diagram is mostly between lymphocytes and neutrophils, and the phenotype is generally normal, which indicates reactive plasma cell hyperplasia, but its clonality needs to be confirmed. In angioimmunoblastic T-cell lymphoma, polyclonal plasma cell increase may occur in samples from different sources; polyclonal plasma cell increase may also occur in patients with new bunyavirus infection, IgG4 disease and tuberculosis infection. Therefore, if plasma cells are found to be elevated in the initial screening tube, it is necessary to closely combine the medical history, and additional tests should be performed to identify the clonality of plasma cells when the number of cells is sufficient.

[0150] 2) B cells: First, in the non-plasma cell gate, use the CD19 / CD20 circle B cell gate to simultaneously + CD20 + Mature B cells and CD19 + CD20 - / + The suspected immature B cells should be gated. If the following conditions occur, B-cell tumors should be suspected:

[0151] ① Abnormal expression intensity of CD19 / CD20 (including enhancement, attenuation, or deletion), or CD19 + CD20 + Mature B cells have obvious grouping on the CD45 / SSC graph, such as increased or decreased CD45 expression, increased or decreased forward scattered light (FSC) / side scattered light (SSC);

[0152] ②The proportion of B cells is high, and most cells abnormally express CD5, which is suspicious for CD5 + B-cell lineage tumors;

[0153] ③ Mature B cells show restricted expression of cell membrane light chains Kappa or Lambda, such as Kappa / Lambda ratio >3:1 or <1:3, or no expression of cell membrane light chains;

[0154] ④ If CD19 appears + CD20 - The B cell population is located in the primitive immature cell area on the CD45 / SSC graph, or CD45 shows negative to weakly positive heterogeneous expression, which is suspected to be immature B cells;

[0155] If the above abnormalities occur, proceed to the next step if the sample quantity permits.

[0156] 3) T cells: Different combinations of gates should be used for analysis. If the following abnormalities occur, T cell tumors should be suspected:

[0157] ① T cells in the lymphocyte gate (CD3 + CD19 - ) has increased significantly;

[0158] ②CD4 in T cell gate + / CD8 + ratio >10:1 or <1:10; or CD4 + CD8 + or CD4 - CD8 - The proportion of T cells increased;

[0159] ③In the gate of all nucleated cells, observe the abnormal expression (loss, enhancement or reduction) of pan-T cell markers (CD3, CD5, CD7). - CD5 + 、CD5 + CD7 - 、CD3 + CD5 - Cell populations with abnormal phenotypes;

[0160] ④In CD3 - CD7 + CD5 appears inside the door + phenotyped cell populations;

[0161] ⑤In CD3 - CD7 - CD5 appears inside the door + or CD4 + (CD4 weakly positive monocytes must be excluded) phenotype of cell population;

[0162] ⑥ Under the nucleated cell gate, if CD5 - CD7 bri+ The cell population is located in the primitive immature cell area or below the lymphocytes in the CD45 / SSC diagram and is suspected to be immature T lymphocytes;

[0163] If the above abnormalities occur, the second step of testing should be carried out if the sample quantity permits.

[0164] 4) NK cells: First, CD3 - CD19 - In the cell gate, CD3 - CD7 + Then, using CD5 / CD56 analysis, the normal NK cell phenotype is CD56 + CD5 - or CD56 + CD5 p+ If CD56 is present + CD5 -If T lymphocytes express or do not express CD8, or CD45 expression is enhanced, and SSC is significantly increased, further NK cell markers are required; if the phenotype is CD7 + CD56 - CD5 - 、CD56 + CD5 + or CD56 - CD5 + For cell populations, it is necessary to compare the position of the cell population in the CD45 / SSC diagram and the expression of CD4, CD8, and CD38 to distinguish whether it is NK cells or abnormal T cells. If it is T cells, refer to the T cell tumor analysis steps and perform a second step of testing.

[0165] 5) Myeloid cells: In the non-plasma cell gate, if an independent cell population appears in the primitive immature cell area, it expresses CD38, CD7 dim+ Or partially expressed, without expression of B-lineage markers CD19 and CD20, suspected to be abnormal myeloid cells (myeloid primitive immature cells, dendritic cells or basophils). Depending on the amount of specimen, further testing is performed to identify whether it is a mixed phenotype and the specific immunophenotype of abnormal myeloid primitive cells and whether immature monocytes are present.

[0166] 6) Non-hematopoietic cells: In the nucleated cell gate, if CD45 - CD56 + If the cell population does not express the hematopoietic cell lineage markers in the initial screening tube, it tends to be non-hematopoietic cells. Non-hematopoietic related markers can be added to further identify whether the abnormal cells are of epithelial or neuroblastic origin.

[0167] First, 20 normal lymph node specimens were selected for testing. All normal lymph nodes were mainly composed of mature lymphocytes and a small amount of granulocytes, monocytes, and plasma cells, strictly following normal proportions, developmental laws, and expression patterns.

[0168] In addition to providing normal lymph nodes as an example of gate logic (such as Figure 1 As shown), one case each of extramedullary multiple myeloma (MM), non-Hodgkin's B-cell lymphoma (B-NHL, DLBCL), B-lymphoblastic lymphoma / leukemia (B-LBL / ALL), non-Hodgkin's T-cell lymphoma (T-NHL, AITL), T-lymphoblastic lymphoma / leukemia (T-LBL / ALL), NK-cell lymphoma and neuroblastoma was provided as an example of the initial screening of the antibody combination. Figure 1 Normal lymph node specimens were described and strictly gated and observed.

[0169] Example results of extramedullary multiple myeloma (MM) initial screening Figure 3As shown, the initial screening results of non-Hodgkin B-cell lymphoma (B-NHL, DLBCL) are as follows Figure 4 As shown, the sample results of the initial screening of B-lymphoblastic lymphoma / leukemia (B-LBL / ALL) are as follows Figure 5 As shown, the initial screening results of non-Hodgkin T-cell lymphoma (T-NHL, AITL) are as follows Figure 6 As shown, the sample results of the initial screening of T-lymphoblastic lymphoma / leukemia (T-LBL / ALL) are as follows Figure 7 As shown, the results of the initial screening of NK cell lymphoma are as follows Figure 8 As shown, the results of the neuroblastoma initial screening are as follows Fig. 9 shown.

[0170] Specifically, if Figure 3 As shown (MM), the Time / CD45 dot plot was used to circle the liquid stability gate with stable flow, the SSC / 7-AAD was used to circle the live cell gate, the FSC-A / FSC-H was used to remove adherent cells to circle the single cell gate, and the FCS-A / SSC-A was used to circle the nucleated cell gate;

[0171] In the nucleated cell gate, CD45 / CD56 and CD45 / CD19 combinations were observed. - CD56 + Abnormal cells; use CD138 / CD38 to circle plasma cells and non-plasma cells, and in the non-plasma cell gate, circle lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations according to CD45 / SSC grouping; analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38, and CD56;

[0172] Observe the abnormal cells with weak CD45 positive and CD56 positive, SSC is similar to monocytes or primitive cells, the cells are large, express CD38, weakly express CD138dim, and do not express CD5, CD4, CD8, CD7, and CD19; (Here is the extramedullary plasmacytoma, the membrane light chain expression is less, if the expression is also weak, express CD38 and CD138, combined with the expression of CD45, CD56 and SSC and clinical history, suspected abnormal plasma cells), can be further improved with cytoplasmic light chain, CD27, CD28, CD117, etc. (the results are as follows Figure 3 shown).

[0173] Specifically, if Figure 4 (B-NHL, DLBCL) as shown: Use the Time / CD45 dot plot to circle the liquid-stable gate, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0174] In the nucleated cell gate, CD45 / CD56 and CD45 / CD19 combinations were used to observe the presence or absence of CD45 - CD56 + Abnormal cells or CD45 - CD19 + Abnormal B cells or plasma cells; use CD138 / CD38 to circle plasma cells and non-plasma cells, and circle lymphocytes, monocytes, granulocytes and CD45 weakly positive or negative cell groups in the non-plasma cell gate according to CD45 / SSC grouping; analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38 and CD56;

[0175] In the non-plasma cell gate, B lymphocytes were circled by CD20 / CD19, and the expression of CD5, membrane light chain Kappa and Lambda of B cells was observed; after the first step of screening, monoclonal expression of membrane light chain Kappa but no Lambda was found in the CD19+ cell population, CD45 was similar to that of normal lymphocytes, and FSC and SSC were slightly larger than those of normal lymphocytes, indicating B cell lymphoma, and further testing of FMC-7, Bcl-2, CD79b, CD10, Ki-67, CD200, CD23, etc. was needed to determine the lymphoma subtype (results as shown in Figure 2). Figure 4 shown);

[0176] Specifically, if Figure 5 (B-LBL / ALL) As shown: Time / CD45 dot plot was used to circle the liquid stability gate with stable flow, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0177] In the nucleated cell gate, CD45 / CD56 and CD45 / CD19 combinations were observed. - CD19 + Abnormal B cells; use CD138 / CD38 to circle plasma cells and non-plasma cells, and in the non-plasma cell gate, circle lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations according to CD45 / SSC grouping; analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38, and CD56;

[0178] In the non-plasma cell gate, B lymphocytes were identified by CD20 / CD19 and CD45 - CD19 +Abnormal B cell CD5, membrane light chain Kappa and Lambda expression;

[0179] After the first step of screening, the CD45 / CD19 combination found abnormal cells with small SSC, negative CD45, expression of CD19, no expression of CD20, CD38, CD7, CD4, CD8, CD5, CD3, CD56, CD138, suspected B-LBL or B-ALL, and further improvement of lineage markers is needed, and naive markers CD34, CD10, TdT and other myeloid companion markers are added (the results are as follows Figure 5 )

[0180] Specifically, if Figure 6 (T-NHL, AITL) as shown:

[0181] ① Use the Time / CD45 dot plot to circle the liquid stability gate when the flow is stable, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0182] ②In the nucleated cell gate, observe the combination of CD45 / CD56 and CD45 / CD19 to see if there is CD45 - CD56 + Abnormal cells or CD45 - CD19 + Abnormal B cells or plasma cells;

[0183] ③ Plasma cells: Use CD138 / CD38 to circle plasma cells and non-plasma cells, and in the non-plasma cell gate, use CD45 / SSC to group lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations; analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38, and CD56;

[0184] ④B cells: circle B lymphocytes in the non-plasma cell gate using CD20 / CD19, and observe the expression of CD5, membrane light chain Kappa and Lambda of B cells;

[0185] ⑤T cells: In the lymphocyte gate, circle CD3 by CD3 / CD19 combination + T cells, CD19 + B cells and CD3 - CD19 - Cell population; in CD3 +The expression of T cell CD4 and CD8 was observed in the T cell gate, and the CD4 / CD8 ratio was calculated. Meanwhile, the expression of T cell CD4, CD8, CD7, CD5 and CD3 was observed in the nucleated cell gate;

[0186] ⑥T / NK cells: in CD3 - CD19 - Within the cell gate, the expression of CD5 on NK cells or abnormal T cells was analyzed using the CD56 / CD7 combination;

[0187] After screening, CD3 - CD19 - In the cell gate, abnormal T lymphocytes expressing CD7, CD4, and CD5 but not CD3, CD56, and CD8 can be seen. The SSC is small, and CD45 is similar to that of normal lymphocytes. Suspected abnormal T lymphocytes in the mature stage express CD4. Further tests such as TRBC1, CD279, CD10, CD30, and CD26 are needed to differentiate angioimmunoblastic T-cell lymphoma, anaplastic T-cell lymphoma, mycosis fungoides, or peripheral T-cell lymphoma not otherwise specified. Molecular tests such as T-cell receptor gene rearrangement and next-generation sequencing can be used to further verify the diagnosis (results such as Figure 6 shown);

[0188] Specifically, if Figure 7 (T-LBL / ALL, ETP) as shown:

[0189] ① Use the Time / CD45 dot plot to circle the liquid stability gate when the flow is stable, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0190] ②In the nucleated cell gate, observe the combination of CD45 / CD56 and CD45 / CD19 to see if there is CD45 - CD56 + Abnormal cells or CD45 - CD19 + Abnormal B cells or plasma cells;

[0191] ③ Plasma cells: Use CD138 / CD38 to circle plasma cells and non-plasma cells, and use CD45 / SSC to group lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations within the non-plasma cell gate;

[0192] After the first step of screening, suspected immature cells with weak CD45 positive expression can be seen in the primitive immature cell area of ​​the CD45 / SSC graph. The phenotype is strongly positive for CD7, weakly positive for CD45 and CD38, and no expression of CD3, CD4, CD5, CD8, CD56, CD19, and CD138. It is necessary to further improve the lineage markers cCD3 and MPO, the immature cell markers CD34, TdT, CD1a, CD99, and other myeloid companion markers CD117, CD13, and CD33 (the results are shown in the figure). Figure 7 shown), etc.

[0193] Specifically, if Figure 8 (NK lymphoma) as shown:

[0194] ① Use the Time / CD45 dot plot to circle the liquid stability gate when the flow is stable, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0195] ②In the nucleated cell gate, observe the combination of CD45 / CD56 and CD45 / CD19 to see if there is CD45 - CD56 + Abnormal cells or CD45 - CD19 + Abnormal B cells or plasma cells;

[0196] ③ Plasma cells: Use CD138 / CD38 to circle plasma cells and non-plasma cells, and use CD45 / SSC to group lymphocytes, monocytes, granulocytes, and CD45 weakly positive or negative cell populations within the non-plasma cell gate;

[0197] Analyze the expression of plasma cell membrane light chains Kappa and Lambda (plasma cells do not express membrane light chains in most cases, but express them in a few cases), CD19, CD45, CD38, and CD56;

[0198] ④B cells: circle B lymphocytes in the non-plasma cell gate using CD20 / CD19, and observe the expression of CD5, membrane light chain Kappa and Lambda of B cells;

[0199] ⑤T cells: In the lymphocyte gate, circle CD3 by CD3 / CD19 combination + T cells, CD19 + B cells and CD3 - CD19 - Cell population; in CD3 +The expression of T cell CD4 and CD8 was observed in the T cell gate, and the CD4 / CD8 ratio was calculated. Meanwhile, the expression of T cell CD4, CD8, CD7, CD5 and CD3 was observed in the nucleated cell gate;

[0200] ⑥T / NK cells: in CD3 - CD19 - Within the cell gate, the expression of CD5 on NK cells or abnormal T cells was analyzed using the CD56 / CD7 combination;

[0201] After screening, CD3 - CD19 - In the cell gate, CD56-positive and CD7-negative abnormal cell groups can be seen. CD45 is strongly positive (stronger than normal lymphocytes). FSC and SSC are larger than normal lymphocytes. They are located in the upper right of normal lymphocytes on the CD45 / SSC graph. They express CD56bri and CD38bri, and some weakly express CD8. They do not express CD7, CD4, CD5, CD3, CD20, CD19, and CD138. Combined with the medical history, abnormal NK cells are suspected, and further improvement of NK cell markers is needed (results are shown in Figure 2). Figure 8 shown), etc.

[0202] Specifically, if Fig. 9 (Non-hematopoietic tumor, neuroblastoma) as shown:

[0203] ① Use the Time / CD45 dot plot to circle the liquid stability gate when the flow is stable, SSC / 7-AAD to circle the live cell gate, FSC-A / FSC-H to remove adherent cells to circle the single cell gate, and FCS-A / SSC-A to circle the nucleated cell gate;

[0204] ②In the nucleated cell gate, CD45 / CD56 and CD45 / CD19 combinations were observed. - CD56 + Abnormal cells account for 97.84% of the nucleated cells. The FSC and SSC are larger than normal lymphocytes. They do not express the hematopoietic cell lineage markers in the initial screening tube, and tend to be non-hematopoietic cells. Considering that the patient is a child and other relevant clinical history, GD2, CD326, and cytokeratin (CK) were added to confirm that GD2 was expressed, but CD326 and CK were not expressed. It is a tumor cell of neuromuscular origin, and neuroblastoma is likely (the results are shown in Figure 2). Fig. 9 Therefore, this antibody combination can also be used to screen and exclude non-hematopoietic tumors;

[0205] In summary, the embodiment of the present application provides a group of antibody compositions for detecting trace tissue samples for screening blood tumors. A combination of multiple flow cytometry antibody markers is used to detect trace tissue samples. Compared with the traditional two-tube method antibody composition, the antibody composition adopts a cocktail combination, 14 antibodies are added to 10 color channels, and a one-tube method is used to screen B, T, NK and plasma cell tumors to avoid too many tubes and too few cells in each tube, which reduces the sensitivity; in addition, one tube of cells can be left for further confirmation, which helps to improve the sensitivity and accuracy of diagnosis.

[0206] At the same time, the embodiment of the present application provides a group of antibody compositions for detecting trace tissue samples to screen blood tumors. 7-AAD antibodies are also used in the initial screening antibody composition, which can effectively exclude necrotic cells in tissue samples and help improve the accuracy of diagnosis; at the same time, the antibody composition is particularly suitable for screening tissue samples with very small cell amounts, especially tissue punctures, skin biopsy tissues, and various endoscopic biopsy specimens, which is beneficial to improve the accuracy of diagnosis.

[0207] Various embodiments of the present application may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present application; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values ​​within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.

[0208] In the present application, in the absence of any contrary description, the directional words used, such as "upper" and "lower", are specifically the directions of the drawings in the accompanying drawings. In addition, in the description of the present specification, the terms "including", "comprising", etc. refer to "including but not limited to". In this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In this article, "and / or" describes the association relationship of the associated objects, indicating that there may be three relationships, for example, A and / or B, which can represent: A exists alone, A and B exist at the same time, and B exists alone. Wherein A, B can be singular or plural. In this article, "at least one" refers to one or more, and "plural" refers to two or more. "At least one", "at least one of the following" or similar expressions refer to any combination of these items, including any combination of singular or plural items. For example, "at least one of a, b, or c", or "at least one of a, b and c", can both mean: a, b, c, ab (i.e. a and b), ac, bc or abc, where a, b, c can be single or plural, respectively.

[0209] The above description is only a specific implementation of the present application, so that those skilled in the art can understand or implement the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features applied for herein.

Claims

1. A group of antibody compositions for detecting trace tissue samples for screening blood tumors, characterized in that: The antibody composition consists of anti-CD5 antibody, anti-CD19 antibody, anti-CD45 antibody, anti-CD4 antibody, anti-kappa antibody, anti-CD56 antibody, anti-Lambda antibody, anti-7-AAD antibody, anti-CD7 antibody, anti-CD3 antibody, anti-CD138 antibody, anti-CD38 antibody, anti-CD20 antibody and anti-CD8 antibody; The volume ratio of the anti-CD5 antibody to the antibody composition is 0.05 to 0.06; The volume ratio of the anti-CD19 antibody to the antibody composition is 0.05 to 0.06; The volume ratio of the anti-CD45 antibody to the antibody composition is 0.07 to 0.08; The volume ratio of the anti-kappa antibody to the antibody composition is 0.02 to 0.03; The volume ratio of the anti-CD4 antibody to the antibody composition is 0.12 to 0.13; The volume ratio of the anti-Lambda antibody to the antibody composition is 0.02 to 0.03; The volume ratio of the anti-CD56 antibody to the antibody composition is 0.12 to 0.13; The volume ratio of the anti-7-AAD antibody to the antibody composition is 0.12 to 0.13; The volume ratio of the anti-CD7 antibody to the antibody composition is 0.05 to 0.06; The volume ratio of the anti-CD3 antibody to the antibody composition is 0.07 to 0.08; The volume ratio of the anti-CD138 antibody to the antibody composition is 0.07 to 0.08; The volume ratio of the anti-CD38 antibody to the antibody composition is 0.07 to 0.08; The volume ratio of the anti-CD8 antibody to the antibody composition is 0.05 to 0.06; The volume ratio of the anti-CD20 antibody to the antibody composition is 0.05 to 0.06; The micro-tissue sample has a cell volume of 1×10 6 The sample volume of each tube should not exceed 150 μL.

2. The antibody composition according to claim 1, characterized in that The antibody composition is a fluorescently labeled antibody composition, and the fluorescent marker used in the fluorescent labeling comprises at least one of the following: At least one of BV605, BV421, V500-C, FITC, PE, PerCP-cy5.5, PE-Cy7, APC, APC-R700 and APC-Cy7.

3. The antibody composition according to claim 2, characterized in that The fluorescein of the anti-CD5 antibody is BV605; and / or, The fluorescein of the anti-CD19 antibody is BV421; and / or, The fluorescein of the anti-CD45 antibody is V500-C; and / or, The fluorescein of the anti-kappa antibody is FITC; and / or, The fluorescein of the anti-CD4 antibody is FITC; and / or, The fluorescein of the anti-Lambda antibody is PE; and / or, The fluorescein of the anti-CD56 antibody is PE; and / or, The fluorescein of the anti-7-AAD antibody is PerCP-cy5.5; and / or, The fluorescein of the anti-CD7 antibody is PE-Cy7; and / or, The fluorescein of the anti-CD3 antibody is APC; and / or, The fluorescein of the anti-CD138 antibody is APC; and / or, The fluorescein of the anti-CD38 antibody is APC-R700; and / or, The fluorescein of the anti-CD8 antibody is APC-Cy7; and / or, The fluorescein of the anti-CD20 antibody is APC-Cy7.

4. The antibody composition according to claim 1, characterized in that The anti-Kappa antibody is a polyclonal antibody.

5. The antibody composition according to claim 1, characterized in that The anti-Lambda antibody is a polyclonal antibody.

6. A group of antibody compositions for detecting trace tissue samples for screening blood tumors, characterized in that: The antibody composition according to any one of claims 1 to 5 is used in a screening reagent for screening trace cell samples.

7. The antibody composition according to claim 6, characterized in that The steps of the screening are: Adding the antibody composition to a trace amount of cell sample in a single sample container, and then performing a first incubation to obtain an incubated sample; The incubation sample and hemolysin are mixed, and a second incubation is performed, followed by centrifugation and PBS washing to obtain a resuspended cell solution; The resuspended cell solution is subjected to flow cytometry detection to complete the screening.

8. The antibody composition according to claim 7, characterized in that The first incubation time is 10 min to 20 min.

9. The antibody composition according to claim 7, characterized in that The second incubation time is ≥5 min.